Recombinant Human TNFSF14 Protein，His

TNFSF14, also known as T cell-activated gene 3 (TCA3) or LIGHT (Lymphotoxin-β, IL-17, and TNF-family member), is a member of the tumor necrosis factor (TNF) superfamily and plays a pivotal role in immune regulation and inflammation. Research into TNFSF14 has gained significant interest due to its involvement in various immune responses and its potential implications in autoimmune diseases, cancer immunotherapy, and viral infections. The protein is primarily expressed by activated T cells and certain other immune cells, facilitating interactions with its receptors, including HVEM (Herpes Virus Entry Mediator) and LTβR (Lymphotoxin-β Receptor), leading to diverse biological activities such as promotion of T cell proliferation, modulation of dendritic cell function, and enhancement of pro-inflammatory cytokine production. Given its dual role in promoting immune responses and its potential contributions to immune-mediated pathologies, researchers are focused on characterizing recombinant TNFSF14 for therapeutic applications. Monoclonal antibodies targeting TNFSF14 or its receptors are being explored in preclinical and clinical settings for their ability to modulate immune responses in diseases like cancer, where immune evasion is a hallmark. Moreover, the study of TNFSF14's structural properties and signaling pathways is essential to unlock its full therapeutic potential, as understanding its interactions with other immune molecules could lead to novel strategies for enhancing anti-tumor immunity or ameliorating autoimmune conditions. Overall, the recombinant expression and functional study of TNFSF14 represent a promising frontier in immunology, providing insights into its complex role in the immune system and potential avenues for innovative therapeutic interventions.